Policy Statement-Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia

被引：168
|
作者：
Watterberg, Kristi L.
Papile, Lu-Ann
Adamkin, David H.
Baley, Jill E.
Bhutani, Vinod K.
Carlo, Waldemar A.
Kumar, Praveen
Polin, Richard A.
Tan, Rosemarie C.
Wang, Kasper S.
Watterberg, Kristi L.
机构：
来源：
PEDIATRICS | 2010年 / 126卷 / 04期
关键词：
bronchopulmonary dysplasia; preterm infant; glucocorticoid; dexamethasone; chronic lung disease; CHRONIC LUNG-DISEASE; BIRTH-WEIGHT INFANTS; EARLY ADRENAL INSUFFICIENCY; LOW-DOSE DEXAMETHASONE; NEONATAL HYDROCORTISONE TREATMENT; PLACEBO-CONTROLLED TRIAL; PRETERM INFANTS; FOLLOW-UP; RANDOMIZED-TRIAL; SCHOOL-AGE;
D O I：
10.1542/peds.2010-1534
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
The purpose of this revised statement is to review current information on the use of postnatal glucocorticoids to prevent or treat bronchopulmonary dysplasia in the preterm infant and to make updated recommendations regarding their use. High-dose dexamethasone (0.5 mg/kg per day) does not seem to confer additional therapeutic benefit over lower doses and is not recommended. Evidence is insufficient to make a recommendation regarding other glucocorticoid doses and preparations. The clinician must use clinical judgment when attempting to balance the potential adverse effects of glucocorticoid treatment with those of bronchopulmonary dysplasia. Pediatrics 2010;126:800-808
引用
收藏
页码：800 / 808
页数：9
相关论文
共 50 条
  • [21] Treatment strategies for bronchopulmonary dysplasia with postnatal corticosteroids in Europe:: the EURAIL survey
    Truffert, P
    Empana, JP
    Bréart, G
    Saugstad, OD
    Goelz, R
    Halliday, HL
    Anceschi, M
    ACTA PAEDIATRICA, 2003, 92 (08) : 948 - 951
  • [22] Inhaled corticosteroids and bronchopulmonary dysplasia
    Isaacs, David
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2018, 54 (12) : 1399 - 1399
  • [23] Corticosteroids and bronchopulmonary dysplasia of the newborn
    Chérif, A
    Marrakchi, Z
    Chaouachi, S
    Boukef, S
    Sfar, R
    ARCHIVES DE PEDIATRIE, 2002, 9 (02): : 159 - 168
  • [24] Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants
    Jefferies, Ann L.
    PAEDIATRICS & CHILD HEALTH, 2012, 17 (10) : 573 - 573
  • [25] Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants
    Blackmon, LR
    Bell, EF
    Engle, WA
    Kanto, WP
    Martin, GI
    Miller, CA
    Rosenfeld, W
    Speer, ME
    Stark, AR
    Barrington, KJ
    Ohlsson, A
    Aziz, K
    Davis, D
    Lee, S
    Sankaran, K
    Van Aerde, J
    PEDIATRICS, 2002, 109 (02) : 330 - 338
  • [26] Can pathophysiological lung function markers guide the use of postnatal corticosteroids for bronchopulmonary dysplasia?
    Kwok, T'ng C.
    Manley, Brett J.
    Roehr, Charles C.
    Sett, Arun
    PEDIATRIC RESEARCH, 2024,
  • [27] Late (æ7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
    Doyle, Lex W.
    Cheong, Jeanie L.
    Ehrenkranz, Richard A.
    Halliday, Henry L.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (10):
  • [28] Late (≥7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
    Doyle, Lex W.
    Cheong, Jeanie L.
    Hays, Susanne
    Manley, Brett J.
    Halliday, Henry L.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (11):
  • [29] Early (∼ 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants
    Doyle, Lex W.
    Cheong, Jeanie L.
    Ehrenkranz, Richard A.
    Halliday, Henry L.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (10):
  • [30] Drugs to Prevent Bronchopulmonary Dysplasia: Effect of Baseline Risk on the Number Needed to Treat
    Jensen, Erik A.
    Roberts, Robin S.
    Schmidt, Barbara
    JOURNAL OF PEDIATRICS, 2020, 222 : 244 - 247
12345